Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.

MLA

Dayan, Gustavo H., et al. “Efficacy of a Monovalent (D614) SARS-CoV-2 Recombinant Protein Vaccine with AS03 Adjuvant in Adults: A Phase 3, Multi-Country Study.” EClinicalMedicine, vol. 64, Sept. 2023, p. 102168. EBSCOhost, https://doi.org/10.1016/j.eclinm.2023.102168.

APA

Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N., Allen, M., Antony, J., Bhate, A. S., Beresnev, T., Bonaparte, M. I., Celle, M., Ceregido, M. A., Corey, L., Fu, B., Grillet, M.-H., Keshtkar-Jahromi, M., Juraska, M., Kee, J. J., Kaali, S., … Sridhar, S. (2023). Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study. EClinicalMedicine, 64, 102168. https://doi.org/10.1016/j.eclinm.2023.102168

Chicago

Dayan, Gustavo H, Nadine Rouphael, Stephen R Walsh, Aiying Chen, Nicole Grunenberg, Mary Allen, Johannes Antony, et al. 2023. “Efficacy of a Monovalent (D614) SARS-CoV-2 Recombinant Protein Vaccine with AS03 Adjuvant in Adults: A Phase 3, Multi-Country Study.” EClinicalMedicine 64 (September): 102168. doi:10.1016/j.eclinm.2023.102168.